Table 3.
Predictors of stent patency.
Variables | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |
Age | 0.996 | 0.950-1.044 | 0.856 | |||
Gender | ||||||
Male | 1 | |||||
Female | 1.489 | 0.689-3.216 | 0.311 | |||
Tumor stage | ||||||
III | 1 | |||||
IV | 0.647 | 0.244-1.718 | 0.647 | |||
ECOG PS | 0.673 | 0.445-1.020 | 0.062 | 0.668 | 0.441-1.012 | 0.057 |
Bismuth type | ||||||
II | 1 | 1 | ||||
III | 0.362 | 0.122-1.075 | 0.067 | 0.354 | 0.119-1.052 | 0.062 |
IV | 0.877 | 0.325-2.363 | 0.795 | 0.827 | 0.306-2.237 | 0.709 |
TBIL before treatment | 1.000 | 0.997-1.004 | 0.841 | |||
TBIL after treatment | 0.993 | 0.980-1.006 | 0.302 | |||
Ca19-9 | 1.000 | 1.000-1.000 | 0.511 | |||
Stent insertion | ||||||
Unilateral | 1 | |||||
Bilateral | 1.090 | 0.510-2.331 | 0.823 | |||
Post-operative chemotherapy | ||||||
No | 1 | |||||
Yes | 1.436 | 0.669-3.081 | 0.353 |
ECOG PS, Eastern Cooperative Oncology Group performance status; TBIL, total bilirubin.